Orano Med, a pioneer in radioligand therapies in oncology, inaugurated the expansion of its R&D Center located in Plano, Texas (USA).

Orano Med Inaugurates Expansion of its U.S ... to develop lead-212-based radioligand therapies by giving our teams the resources they need to advance a growing pipeline of drug candidates ...

Orano Med, a subsidiary of the ... The expansion includes around 5,000 ft² of new laboratory space, enabling the advancement of a growing pipeline and doubling the Good Manufacturing Practice ...

Approximately 75,000 new residents are expected to move to Knox County by 2040. Who are they, and where are they coming from?

Molecular Partners AG and Orano Med have announced the development of MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) for ovarian cancer treatment, which shows promising tumor ...

Sanofi's investment raises the value of Orano Med to €1.9 billion and gives it a 16% stake in the company, which focuses on the development of radiotherapies based on lead-212, an isotope that ...

The Orano-Bond has a maturity date of 3/12/2031 and offers a coupon of 4.0000%. The payment of the coupon will take place 1,0 times per Year on the 12.03.. At the current price of 103.045 EUR this ...

In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology ...

An estimated 3,500 barrels of oil spilled in a field near Fort Ransom, N.D., and the release was contained, the pipeline’s operator said. By Amanda Holpuch Cameron M. Smith, 50, a Canadian who ...

Novo on Sunday said full results from two late-stage trials of CagriSema - one in people with obesity or overweight, the ...

Indeed, select companies developing Pb-212-based assets — such as ArtBio, AdvanCell, Perspective Therapeutics and Orano Med — have developed their own Pb-212 generator production capabilities.